Oncology

Global cancer drug market to grow to $111 billion by 2020: report

Global cancer drug market to grow to $111 billion by 2020: report

By

The global cancer market is expected to reach $111 billion by 2020, according to new market research, with immunotherapies—particularly in lung cancer—expected to drive growth.

UK doctors lobby for off-label Avastin use

Doctors want the National Health Service to allow them to prescribe the oncology drug for wet age-related macular degeneration.

Study shows Lucentis at Eylea disadvantage

Study shows Lucentis at Eylea disadvantage

By

An NIH study shows possible limit to Lucentis's appeal.

Five things for pharma marketers to know: Friday, February 13

Five things for pharma marketers to know: Friday, February 13

By

FDA approves Eisai's thryoid cancer drug two months early, Gilead and Germany agree to a Sovaldi price cut, and Valeant looks set to make a bid for Salix.

Study shows impact of the "Angelina Jolie effect"

Study shows impact of the "Angelina Jolie effect"

By

AARP researchers found that the celebrity's decision to go public triggered a surge in genetic screening.

Five things for pharma marketers to know: Thursday, February 12

Five things for pharma marketers to know: Thursday, February 12

By

Hospira is planning a Lucentis biosimilar, Roche is expanding is cancer diagnostics portfolio, and cholesterol may not be as bad as originally thought (but smoking is worse than ever).

Survey shows cancer cause-effect awareness lacking

A survey showed patients are not really clear on what causes cancer.

Pfizer Ibrance is first approved CDK inhibitor

Pfizer Ibrance is first approved CDK inhibitor

By

The FDA approved the breast cancer drug Tuesday afternoon. Estimated peak sales: $3.8 billion.

Lilly expands Trulicity marketing push, lowers 2015 guidance

Lilly expands Trulicity marketing push, lowers 2015 guidance

By

The drugmaker says its Trulicity focus now includes primary care doctors in addition to specialists, and that foreign exchange will take a bite out of 2015 performance.

Five things for pharma marketers to know: Friday, January 30

Five things for pharma marketers to know: Friday, January 30

By

Obama's precision medicine initiative looks set for bipartisan support, Valeant has offered $296 million to buy Dendreon and researchers say Roche's Tamiflu works.

J&J's Imbruvica snares fourth indication

J&J's Imbruvica snares fourth indication

By

The label will now include Waldenstrom's macroglubulinemia.

Amgen, Novartis, BMS map future

Amgen, Novartis, BMS map future

By

Amgen execs assert there is still a future for 15-year-old Enbrel, Novartis sees off-label Avastin use pinch Lucentis sales and BMS has expanded its field force in anticipation of an Opdivo push.

Five things for pharma marketers to know: Tuesday January 27

Five things for pharma marketers to know: Tuesday January 27

By

AstraZeneca's Nexium now has generic competition, toxicity worries researchers about new cancer approaches and a former Pfizer exec will now lead an e-cigarette company.

New cancer therapies raise new safety concerns

Two new classes of medicines have shown unparalleled efficacy in oncology, but there are growing concerns about the treatments' safety.

News hints at BMS-Merck PD-1 lung cancer tussle

News hints at BMS-Merck PD-1 lung cancer tussle

By

News flowing from Bristol-Myers Squibb and Merck show the two companies may fight for elbow room among lung cancer patients with drugs that have already started building credibility in other indications.

Pfizer cancer drug skips FDA advisory panel

Pfizer cancer drug skips FDA advisory panel

By

The FDA told Pfizer that it isn't bothering with a committee review for the experimental breast cancer drug Ibrance (palbociclib). The part two news exciting investors: Pfizer and the FDA are already talking labels.

Novartis to leverage DNA-editing tool for immunotherapy

The drugmaker has signed a deal with two biotechs with novel gene-sequencing capabilities.

Five things for pharma marketers to know: Tuesday, December 30

Five things for pharma marketers to know: Tuesday, December 30

By

NIH project for genome sequencing of newborns commences; remote care, next-gen. DNA sequencing top list of 2014 healthcare-market trends; WHO plans evaluation of contagious-disease response.

Early Opdivo OK gives BMS more time to erase Keytruda's lead

Early Opdivo OK gives BMS more time to erase Keytruda's lead

By

FDA's accelerated approval on the checkpoint inhibitor chips away at Merck's first-mover advantage in the US market.

Five things for pharma marketers to know: Tuesday, December 23

Five things for pharma marketers to know: Tuesday, December 23

By

BMS cancer drug Opdivo becomes the second PD-1 inhibitor to secure US approval ; Omnicare hit by more kickback charges; India looks to rein in pharma marketing.

Five things for pharma marketers to know: Monday, December 22

Five things for pharma marketers to know: Monday, December 22

By

Express Scripts taps AbbVie hep. C drug as exclusive option; AZ first-in-class cancer drug approved; Cubist gains OK for superbug fighter.

Merck buys Swiss biotech

The drugmaker announced it will acquire OncoEthix and its oncology candidate OTX015 in a deal worth up to $365 million

Five things for pharma marketers to know: Thursday, December 18

Five things for pharma marketers to know: Thursday, December 18

By

Shire may bid on NPS Pharmaceuticals; Amgen says cancer drug will cost $178,000; Takeda has a new head of R&D.

Brain cancer candidate touted for melanoma

Studies by Australian company Novogen are said to demonstrate, for the first time, that a drug highly effective against brain cancers has the same high potency against melanoma.

Genentech drug combo targets advanced melanoma

The treatment reduces risk by half compared to widely used Zelboraf.

FDA 2014 approvals outpace those of 2013

FDA 2014 approvals outpace those of 2013

By

The regulator noted in its early 2014 retrospective that it set a high mark for the number of approved rare disease drugs this year, and that insufficient information is the reason many breakthrough status requests get bounced.

Five things for pharma marketers to know: Monday, December 15

Five things for pharma marketers to know: Monday, December 15

By

United Healthcare tests an all-in-one cancer payment model, Pfizer inks a worldwide commercialization license for a human growth factor hormone, and the Commonwealth Fund grades Medicare as the program nears its 50th.

Merck rolls out new Keytruda data in hard-to-treat group

Merck rolls out new Keytruda data in hard-to-treat group

By

The drugmaker shared early-trial results for its PD-1 among hard-to-tread triple-negative breast cancer patients and announced an effort to see if the drug can help patients overcome treatment resistance.

AbbVie oncology pipeline continues to show progress

AbbVie oncology pipeline continues to show progress

By

Early trials of Venetoclax, formerly known as ABT-199, indicate the experimental drug execs consider an oncology cornerstone continues to show promise.

Array gets binimetinib all to itself

Transfer of rights to the experimental cancer drug hinges on completion of Novartis/GSK asset swap.

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.

Email Newsletters